{'52WeekChange': 0.77659583,
 'SandP52WeekChange': None,
 'address1': '130 Eileen Stubbs Avenue',
 'address2': 'Suite 19',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 5.07,
 'askSize': 4000,
 'averageDailyVolume10Day': 3367487,
 'averageVolume': 1672255,
 'averageVolume10days': 3367487,
 'beta': 2.032632,
 'beta3Year': None,
 'bid': 5.01,
 'bidSize': 800,
 'bookValue': 0.186,
 'category': None,
 'circulatingSupply': None,
 'city': 'Dartmouth',
 'companyOfficers': [],
 'country': 'Canada',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.1,
 'dayLow': 4.71,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 306504192,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '902-492-0888',
 'fiftyDayAverage': 3.4765716,
 'fiftyTwoWeekHigh': 6.82,
 'fiftyTwoWeekLow': 1.35,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 54827976,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 62,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.07798,
 'heldPercentInstitutions': 0.19532,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1525910400,
 'lastSplitFactor': '312:1000',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/imv-inc.com',
 'longBusinessSummary': 'IMV Inc., a clinical-stage immuno-oncology company, '
                        'together with its subsidiaries, develops products '
                        'based on its platform and products with a primary '
                        'focus on T cell activating therapies for cancer. The '
                        "company's DPX drug development platform provides a "
                        'patented delivery formulation that enables controlled '
                        'and prolonged exposure of antigens to the immune '
                        'system. The company develops DPX-Survivac, T cell '
                        'activating immunotherapy that is in Phase II clinical '
                        'trials for ovarian cancer and diffuse large B-cell '
                        'lymphoma. It also develops DPX-RSV, a B cell epitope '
                        'peptide vaccine candidate, which has completed a '
                        'Phase I clinical trial for respiratory syncytial '
                        'virus; DPX-E7 an investigational immunotherapy that '
                        'targets a viral protein in human papillomavirus (HPV) '
                        'known as E7; and vaccine candidates for malaria and '
                        'the Zika virus. IMV Inc. has collaboration and '
                        'license agreements with Merck & Co., Inc., '
                        'Dana-Farber Cancer Institute, Incyte Corporation, and '
                        'Leidos Inc, as well as with Zoetis and The Wistar '
                        'Institute; and a preclinical therapeutic research '
                        'collaboration with Navidea Biopharmaceuticals, Inc. '
                        'to explore the potential combinatory effect with '
                        'their platform-based immunotherapies. The company was '
                        'formerly known as Immunovaccine Inc. and changed its '
                        'name to IMV Inc. in May 2018. IMV Inc. was founded in '
                        '2000 and is headquartered in Dartmouth, Canada.',
 'longName': 'IMV Inc.',
 'market': 'us_market',
 'marketCap': 313134880,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_7828330',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.91,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '902-492-1819',
 'previousClose': 5.01,
 'priceHint': 2,
 'priceToBook': 27.258064,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.1,
 'regularMarketDayLow': 4.71,
 'regularMarketOpen': 4.91,
 'regularMarketPreviousClose': 5.01,
 'regularMarketPrice': 4.91,
 'regularMarketVolume': 1035175,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 61695300,
 'sharesPercentSharesOut': 0.006,
 'sharesShort': 373089,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 369583,
 'shortName': 'IMV Inc.',
 'shortPercentOfFloat': None,
 'shortRatio': 0.94,
 'startDate': None,
 'state': 'NS',
 'strikePrice': None,
 'symbol': 'IMV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.339,
 'twoHundredDayAverage': 3.0524461,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b688920e-dd36-3f43-8f4d-f7e9d38b8b28',
 'volume': 1035175,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://imv-inc.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'B3B 2C4'}